Cardinal Health: Distribution Scale Drives Margin Recovery, Raises Fiscal 2026 Guidance
- Cardinal Health's distribution scale and cost discipline drove 19% revenue growth to $65.6B and stronger margins. • Pharmaceutical and Specialty Solutions led recovery, revenue rose to $60.7B and all segments posted double‑digit profit growth. • Cardinal raised fiscal 2026 non‑GAAP EPS guidance, completed $750M buybacks, and reached its targeted leverage range.
Distribution scale fuels margin recovery
Cardinal Health reports a marked improvement in operational performance in its second quarter of fiscal 2026 as distribution scale, cost discipline and integration of recent acquisitions drive profit growth. Revenue rises 19% year‑over‑year to $65.6 billion, while GAAP operating earnings increase to $707 million and non‑GAAP operating earnings climb 38% to $877 million, reflecting stronger margins across distribution and specialty channels. Management attributes the gains to pricing and volume dynamics in its core distribution business and tighter cost control across the enterprise.
The company’s Pharmaceutical and Specialty Solutions segment leads the recovery, with revenue expanding to $60.7 billion from $50.8 billion a year earlier and all five operating segments delivering at least double‑digit segment profit growth. Cardinal points to sustained demand across healthcare services and successful integration of recent acquisitions as central drivers, enabling better network utilization and higher throughput in distribution centers. Margin expansion comes from both operational execution and targeted efficiency measures that lower per‑unit costs even as volumes rise.
Improved profitability is supported by balance‑sheet actions that reduce share count and position the company for continued investment. Non‑GAAP diluted EPS increases to $2.63, helped by completed share repurchases and ongoing cost management, although higher interest and other financing expenses related to earlier acquisitions partially offset earnings gains. CEO Jason Hollar’s strategic priorities — focusing on operational excellence, portfolio integration and disciplined capital allocation — remain the narrative management emphasizes as the company scales distribution and specialty services.
Guidance raise, buybacks and leverage
Cardinal raises its fiscal 2026 non‑GAAP EPS guidance to a range of $10.15 to $10.35 and completes its annual baseline share repurchase program of $750 million, saying it has reached its targeted leverage range. The company signals confidence that combined operating improvements and balance‑sheet management underpin the higher outlook.
Tax profile and capital priorities
Cardinal notes a stable non‑GAAP effective tax rate of 21.4% while the GAAP effective tax rate rises to 25.2% in the quarter. Management reiterates capital allocation priorities — reinvestment in the business, debt reduction and shareholder returns — and flags that financing costs tied to prior acquisitions remain an elevated but managed headwind.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…